Group 1 - Dongcheng Pharmaceutical experienced a decline of 5.08% on August 27, with a stock price of 16.62 yuan per share and a trading volume of 372 million yuan, resulting in a total market capitalization of 13.705 billion yuan [1] - The company, established on December 31, 1998, and listed on May 25, 2012, specializes in the research, production, and sales of heparin sodium raw materials and chondroitin sulfate [1] - The revenue composition of Dongcheng Pharmaceutical includes 44.16% from raw materials, 36.38% from nuclear medicine products, 13.17% from formulations, and 6.30% from other sources [1] Group 2 - The Guotou Ruijin Fund holds a significant position in Dongcheng Pharmaceutical, with the Guotou Ruijin Healthcare Mixed A Fund (000523) owning 229,800 shares, representing 2.43% of the fund's net value, making it the tenth largest holding [2] - The Guotou Ruijin Healthcare Mixed A Fund has a total scale of 1.21 billion yuan and has achieved a return of 37.81% year-to-date, ranking 1195 out of 8194 in its category [2] - The fund has a one-year return of 52.78%, ranking 2179 out of 7963, and a cumulative return of 162% since its inception on February 25, 2014 [2]
东诚药业股价跌5.08%,国投瑞银基金旗下1只基金重仓,持有22.98万股浮亏损失20.45万元